Glenmark barred by HC from selling its anti-diabetes drugs

Written By Unknown on Sabtu, 21 Maret 2015 | 21.03

A bench of justices S Ravindra Bhat and Najmi Waziri, while granting an interim injunction in favour of MSD, also said the price difference between the drugs of the two companies "is not so startling as to compel the court to infer that allowing Glenmark to sell the drug at depressed prices would result in increased access".

Indian pharma major Glenmark pharamceuticals  was on Saturday barred by the Delhi High Court from making, marketing or selling its anti-diabetes medicines on the ground that it had "prima facie" infringed the patent of US drug major Merck Sharp and Dohme (MSD).

A bench of justices S Ravindra Bhat and Najmi Waziri, while granting an interim injunction in favour of MSD, also said the price difference between the drugs of the two companies "is not so startling as to compel the court to infer that allowing Glenmark to sell the drug at depressed prices would result in increased access".

Glenmark's medicines, Zita and Zita-Met, cost 30 percent less than MSD's Januvia and Janumet, which is due to the customs duty paid by the US firm, the court said and added "no allegation has been made that MSD today sells its drugs at a relatively high price that hinders access to the drug".

"In the present case, given the size of the diabetes drug market in India and the sheer number of patients from all economic strata of society, demand for low-priced medicines will remain, rather than any distortion of demand, due to brand loyalty or a first mover's advantage to MSD," it said.

"A strong case can in some instances offset an equal balance of conveniences between parties. In this case, MSD has established a prima facie case of infringement,...," it also said.

The bench, however, allowed Glenmark to to sell the products in question which are already in the market (i.e. with its distributors, retailers etc.). "However, in compliance with the injunction granted in favour of the plaintiff/MSD – it shall not henceforth further sell, distribute or in any manner take any steps towards placing in the market the drug in question, Zita and Zitamet and such of the pharmaceutical products which are covered by the claim for interim injunction in the suit," it said.

It directed Glenmark to give a true and correct account of all stock of its anti-diabetes drugs in its factory as well as those which are in the market and permitted to be sold. 

Glenmark stock price

On March 20, 2015, Glenmark Pharma closed at Rs 830.90, down Rs 21.8, or 2.56 percent. The 52-week high of the share was Rs 879.05 and the 52-week low was Rs 546.60.


The company's trailing 12-month (TTM) EPS was at Rs 18.02 per share as per the quarter ended December 2014. The stock's price-to-earnings (P/E) ratio was 46.11. The latest book value of the company is Rs 107.12 per share. At current value, the price-to-book value of the company is 7.76.


Anda sedang membaca artikel tentang

Glenmark barred by HC from selling its anti-diabetes drugs

Dengan url

http://kebugaranhidup.blogspot.com/2015/03/glenmark-barred-by-hc-from-selling-its.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Glenmark barred by HC from selling its anti-diabetes drugs

namun jangan lupa untuk meletakkan link

Glenmark barred by HC from selling its anti-diabetes drugs

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger